A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate - Concepedia

Concepedia

Publication | Open Access

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

DOI Full Paper Access

2.1K

Citations

17

References

1999

Year

Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst, Ken J. Bulpitt, Roy Fleischmann, Robert I. Fox, Christopher G. Jackson, M. Lange, Daniel Burge

New England Journal of Medicine

Abstract

In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than methotrexate alone.

References

	Year	Citations

Page 1